Sunday, July 22, 2018 10:15:51 AM
Brilacidin wasn't pulled from research. The phIII ABSSSI was postponed due to costs being higher due to FDA wanting a larger trial than they had expected. The intention is to move it forward once funds permit it. If the Prurisol trial shows good results I'm hoping the company sells or partners it off so that they can flush out the various usages for Brilacidin. However, we may end up with a partner or outright sale of Brilacidin. Time will tell.
This article is two years old, but, it outlines the companies intentions with Brilacidin. https://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino
In Reply to 'Empiricst1'
Basil, I agree with your post, but there are some reputable posters (Rayon/Ray from the old Yahoo board and from KarinCA's board, for example) that feel that B was pulled off the shelf because of potentially strong side effects. I see that as a possibility, but feel the need for newer anti-biotics that can deal with some of the new MDR bacterial strains would be useful regardless. But, as noted, all taken together, I agree with what you are saying, fwiw. GL
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM